Caris Life Sciences

Caris and collaborators within the Caris Precision Oncology Alliance (Caris POA) collectively presented 19 studies across a range of breast cancer types at the San Antonio Breast Cancer Symposium (SABCS). Here’s a glimpse at a few of the presentations: 🔹 Slide 1: Comprehensive Characterization of PTEN loss by IHC and PTEN alteration by NGS in Metastatic HR-Positive, HER2-Negative Breast Cancer-- An Exploratory Analysis of Biomarker Concordance and Co-Occurrence ▪️ Presenter: Jennifer Klemp, PhD, MPH, MA 🔹 Slide 2: Outcomes in patients with PIK3CA-mutated breast cancer treated with metformin ▪️Presenter: Rosemary Plagens, PhD 🔹 Slide 3: Evaluation of steroid hormone receptor expression and clinical outcomes in ER-positive breast cancer bone metastases ▪️Presenter: Anthony Rossi 🔹 Slide 4: TONSL, an immortalizing oncogene on Chr.8q24.3 amplicon, confers intrinsic resistance to CDK4/6 inhibitors in breast cancer ▪️Presenter: Harikrishna Nakshatri 🔹 Slide 5: Tertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) breast cancer (BC) in the Real-World Database ▪️Presenter: Saranya Chumsri 🔹 Slide 6: Chemokine signatures improve PD-L1-based prediction of pembrolizumab response in triple-negative breast cancer ▪️Presenter: Sachin Deshmukh, PhD 🔹 Slide 7: Site-specific Genomic and Immune Landscapes Underpinning in metastatic Male Breast Cancer ▪️Presenter: Dario Trapani

Curious about how ESR1 mutations influence response to elacestrant? Don’t miss Caris’ Chief Medical Officer, Dr. George Sledge, Jr. presenting his Spotlight Poster during #SABCS25. https://bit.ly/3XHVBFe

#SABCS25 is underway. Stop by Booth 209 to meet with the Caris Life Sciences team and explore how our molecular profiling and AI-driven insights are shaping the future of oncology. We’re ready to connect: https://bit.ly/4ovX0tz

Today during #SABCS25, researchers presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences® (Caris) focused on transforming recurrence risk assessment in early-stage breast cancer through artificial intelligence (AI). “By integrating imaging, clinical data, and molecular profiling, we are advancing beyond single-dimension diagnostics to deliver a more precise and comprehensive understanding of recurrence risk in breast cancer,” said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. Learn more: https://ow.ly/J2O050XHb3G

Discover why multimodal testing is crucial for comprehensive biomarker detection in breast cancer. Check out Jennifer Klemp, PhD, MPH, MA's poster at #SABCS25 to learn more: https://bit.ly/3XHVBFe

Catch Caris’ second #SABCS25 talk this afternoon, where Dr. Eleftherios Mamounas will share data on the clinical utility of multimodal AI models for predicting distant recurrence risk in HR+ early breast cancer. Learn more: https://bit.ly/3XHVBFe

Congratulations to the Caris Life Sciences Team; Drs. Sparano, Sledge, Chen; ECOG and the NCI Cooperative Groups for this excellent presentation showing the power of Multimodal AI models combining clinical, molecular, and pathology imaging data to improve prediction for early and late breast cancer recurrence in the pivotal TAILORx trial #SABCS

Caris’ multimodal AI research takes center stage this morning at #SABCS25. Dr. Joseph Sparano will present results from our innovative study on recurrence prediction and risk stratification in breast cancer. https://bit.ly/3XHVBFe

Join Caris at the San Antonio Breast Cancer Symposium to explore the next era of cancer diagnostics. Stop by booth 209 to meet our team and discover how our advanced molecular profiling solutions are helping redefine cancer care. https://bit.ly/4ovX0tz #SABCS25

Register Today! ✅ Join Caris Life Sciences and Dr. Jai Patel, PharmD, as we explore the clinical impact of DPYD testing, the evidence from ongoing trials, and the advocacy driving change across oncology. Gain insight into why precision dosing is becoming a new frontier in personalized medicine. Don't miss this discussion: https://lnkd.in/gpaxNSFq